Table 1.
Baseline characteristics of patients and study eyes
| Parameters | Study population (n=156) |
|---|---|
| Mean age, years (SD) | 63.4 (11.3) |
| Race, n (%) | |
| White | 109 (69.9) |
| Black/African-American/Asian | 15 (9.6) |
| Not recorded | 32 (20.5) |
| Type of diabetes, n (%) | |
| Type 1 | 13 (8.3) |
| Type 2 | 126 (80.8) |
| Not recorded | 17 (10.9) |
| HbA1c, n (%) | |
| ≤8% | 68 (43.6) |
| 9%–12% | 16 (10.3) |
| ≥13% | 2 (1.3) |
| Not recorded | 70 (44.9) |
| Diabetic retinopathy (NPDR) severity, n (%) | |
| Mild | 22 (14.1) |
| Moderate | 55 (35.3) |
| Severe | 17 (10.9) |
| Not recorded | 62 (39.7) |
| Median time since DME diagnosis, weeks | 2 |
| Mean (range) | 51 (0–609) |
| History of procedures in study eye, n (%) | |
| Retinal focal laser | 63 (40.4) |
| Panretinal photocoagulation | 23 (14.7) |
| Pars plana vitrectomy | 6 (3.8) |
| Intravitreal triamcinolone acetonide injection | 4 (2.6) |
| Lens status, n (%) | |
| Phakic | 104 (66.7) |
| Pseudophakic | 51 (32.7) |
| Not recorded | 1 (0.6) |
| Mean BCVA, ETDRS lines (SD) | 11.8 (3.5) 20/63−1 Snellen |
| Mean CRT, μm (SD) | 413 (105) |
Abbreviations: BCVA, best-corrected visual acuity; CRT, central retinal thickness; DME, diabetic macular edema; ETDRS, Early Treatment Diabetic Retinopathy Study; HbA1c, glycated hemoglobin; NPDR, nonproliferative diabetic retinopathy; SD, standard deviation.